AACR24: EpicentRx’s phase 2a using TGF-β trap to overcome checkpoint resistance
- blonca9
- Apr 9, 2024
- 1 min read
EpicentRx CEO Tony Reid and MD Andersen investigator Anthony Conley describe the data presented at AACR showing how TGF-β might be used to turn cold tumors hot.